EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

Larissa L. Fujii-Lau; Barham K. Abu Dayyeh; Marco J. Bruno; Kenneth J. Chang; John M. Dewitt; Paul Fockens; David Forcione; Bertrand Napoleon; Laurent Palazzo; Mark D. Topazian; Maurits J. Wiersema; Amitabh Chak; Jonathan E. Clain; Douglas O. Faigel; Ferga C. Gleeson; Robert Hawes; Prasad G. Iyer; Elizabeth Rajan; Tyler Stevens; Michael B. Wallace; Kenneth K. Wang; Michael J. Levy

doi:10.1016/j.gie.2014.10.035

EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

Larissa L. Fujii-Lau, Barham K. Abu Dayyeh, Marco J. Bruno, Kenneth J. Chang, John M. Dewitt, Paul Fockens, David Forcione, Bertrand Napoleon, Laurent Palazzo, Mark D. Topazian, Maurits J. Wiersema, Amitabh Chak, Jonathan E. Clain, Douglas O. Faigel, Ferga C. Gleeson, Robert Hawes, Prasad G. Iyer, Elizabeth Rajan, Tyler Stevens, Michael B. WallaceKenneth K. Wang, Michael J. Levy

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Background Detection of hepatic metastases during EUS is an important component of tumor staging. Objective To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses. Design Retrospective study, survey. Setting Single, tertiary-care referral center. Patients Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period. Interventions EUS-FNA of solid hepatic masses. Main Outcome Measurements Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy. Results A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. Limitations Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria. Conclusion An EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.

Original language	English (US)
Pages (from-to)	1188-1196.e7
Journal	Gastrointestinal endoscopy
Volume	81
Issue number	5
DOIs	https://doi.org/10.1016/j.gie.2014.10.035
State	Published - May 1 2015

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Gastroenterology

Access to Document

10.1016/j.gie.2014.10.035

Cite this

Fujii-Lau, L. L., Abu Dayyeh, B. K., Bruno, M. J., Chang, K. J., Dewitt, J. M., Fockens, P., Forcione, D., Napoleon, B., Palazzo, L., Topazian, M. D., Wiersema, M. J., Chak, A., Clain, J. E., Faigel, D. O., Gleeson, F. C., Hawes, R., Iyer, P. G., Rajan, E., Stevens, T., ... Levy, M. J. (2015). EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses. Gastrointestinal endoscopy, 81(5), 1188-1196.e7. https://doi.org/10.1016/j.gie.2014.10.035

Fujii-Lau, LL, Abu Dayyeh, BK, Bruno, MJ, Chang, KJ, Dewitt, JM, Fockens, P, Forcione, D, Napoleon, B, Palazzo, L, Topazian, MD, Wiersema, MJ, Chak, A, Clain, JE, Faigel, DO, Gleeson, FC, Hawes, R, Iyer, PG, Rajan, E, Stevens, T, Wallace, MB , Wang, KK & Levy, MJ 2015, 'EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses', Gastrointestinal endoscopy, vol. 81, no. 5, pp. 1188-1196.e7. https://doi.org/10.1016/j.gie.2014.10.035

@article{890b5c794dc84e489b29b51d8d600fbd,

title = "EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses",

abstract = "Background Detection of hepatic metastases during EUS is an important component of tumor staging. Objective To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses. Design Retrospective study, survey. Setting Single, tertiary-care referral center. Patients Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period. Interventions EUS-FNA of solid hepatic masses. Main Outcome Measurements Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy. Results A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. Limitations Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria. Conclusion An EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.",

author = "Fujii-Lau, {Larissa L.} and {Abu Dayyeh}, {Barham K.} and Bruno, {Marco J.} and Chang, {Kenneth J.} and Dewitt, {John M.} and Paul Fockens and David Forcione and Bertrand Napoleon and Laurent Palazzo and Topazian, {Mark D.} and Wiersema, {Maurits J.} and Amitabh Chak and Clain, {Jonathan E.} and Faigel, {Douglas O.} and Gleeson, {Ferga C.} and Robert Hawes and Iyer, {Prasad G.} and Elizabeth Rajan and Tyler Stevens and Wallace, {Michael B.} and Wang, {Kenneth K.} and Levy, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2015 American Society for Gastrointestinal Endoscopy.",

year = "2015",

month = may,

day = "1",

doi = "10.1016/j.gie.2014.10.035",

language = "English (US)",

volume = "81",

pages = "1188--1196.e7",

journal = "Gastrointestinal endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

AU - Fujii-Lau, Larissa L.

AU - Abu Dayyeh, Barham K.

AU - Bruno, Marco J.

AU - Chang, Kenneth J.

AU - Dewitt, John M.

AU - Fockens, Paul

AU - Forcione, David

AU - Napoleon, Bertrand

AU - Palazzo, Laurent

AU - Topazian, Mark D.

AU - Wiersema, Maurits J.

AU - Chak, Amitabh

AU - Clain, Jonathan E.

AU - Faigel, Douglas O.

AU - Gleeson, Ferga C.

AU - Hawes, Robert

AU - Iyer, Prasad G.

AU - Rajan, Elizabeth

AU - Stevens, Tyler

AU - Wallace, Michael B.

AU - Wang, Kenneth K.

AU - Levy, Michael J.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background Detection of hepatic metastases during EUS is an important component of tumor staging. Objective To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses. Design Retrospective study, survey. Setting Single, tertiary-care referral center. Patients Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period. Interventions EUS-FNA of solid hepatic masses. Main Outcome Measurements Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy. Results A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. Limitations Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria. Conclusion An EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.

AB - Background Detection of hepatic metastases during EUS is an important component of tumor staging. Objective To describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses. Design Retrospective study, survey. Setting Single, tertiary-care referral center. Patients Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period. Interventions EUS-FNA of solid hepatic masses. Main Outcome Measurements Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy. Results A total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. Limitations Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria. Conclusion An EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.

UR - http://www.scopus.com/inward/record.url?scp=84927576278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927576278&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2014.10.035

DO - 10.1016/j.gie.2014.10.035

M3 - Article

C2 - 25660980

AN - SCOPUS:84927576278

SN - 0016-5107

VL - 81

SP - 1188-1196.e7

JO - Gastrointestinal endoscopy

JF - Gastrointestinal endoscopy

IS - 5

ER -

EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this